Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.6m USD

Net Margin
Taysha Gene Therapies Inc

-1 071.6%
Current
-1 157%
Average
-7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 071.6%
=
Net Income
-89.3m
/
Revenue
8.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
352.5m USD
-1 072%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
8%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
12%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
121.1B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
32.9B EUR
38%

Taysha Gene Therapies Inc
Glance View

Market Cap
352.5m USD
Industry
Biotechnology

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas and currently employs 178 full-time employees. The company went IPO on 2020-09-24. The firm is focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). Its portfolio of gene therapy candidates targets a range of neurological indications across three distinct therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Its product candidates include TSHA-101, which is being developed for the treatment of giant axonal neuropathy (GAN); TSHA-102, a neurodevelopmental disorder product candidate, which is being developed for the treatment of Rett syndrome; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter, and TSHA-105, a gene replacement therapy for the treatment of SLC13A5 deficiency.

TSHA Intrinsic Value
2.85 USD
Undervaluation 40%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 071.6%
=
Net Income
-89.3m
/
Revenue
8.3m
What is the Net Margin of Taysha Gene Therapies Inc?

Based on Taysha Gene Therapies Inc's most recent financial statements, the company has Net Margin of -1 071.6%.

Back to Top